Molecular Cancer Therapeutics Journal

Overview
Identity
View All

publication venue for

Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years 2018
Abstract B29: A multicenter, open-label phase 1/2 study of oral CFG920, in combination with prednisone in adult patients with metastatic castration-resistant prostate cancer 2015
Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). 2011
Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers. 2011
Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503). 2011
Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors 2009
Abstract B54: A phase 1 study to assess the safety, tolerability and pharmacokinetics of the ErbB-family inhibitor ARRY-334543 in patients with advanced solid tumors 2009
Proapoptotic versus prosurvival function of the MAP kinase p38 induced by HDAC inhibitor in hematological malignant cells 2009
A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms 2007
AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium 2007
Fluororescence in situ hybridization (FISH) gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors (MSGT) treated with lapatinib 2007
Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers 2007
SNS-595 demonstrates initial clinical activity in a phase 2 trial in platinum resistant epithelial ovarian cancer 2007
A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.
Abstract A109: Targeting pyrimidine biosynthesis as a metabolic vulnerability in brain metastasis. 22:A109-A109. 2023
Abstract A158: Rational development of synergistic therapies alongside BMI1 Inhibition for group 3 medulloblastoma. 22:A158-A158. 2023
Abstract C053: BACE1 cleaves EGFR to drive lung adenocarcinoma brain metastasis. 22:C053-C053. 2023
Abstract C082: SCD1 is a potent therapeutic target in MYC-amplified group 3 medulloblastoma. 22:C082-C082. 2023
Abstract C097: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. 22:C097-C097. 2023
Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591). 20:P035-P035. 2021
Estrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia. 16:2618-2626. 2017
Abstract B181: TP53 mutation screening in patients with recurrent platinum-sensitive ovarian cancer.. 12:B181-B181. 2013
Abstract C184: Thyroid hormone receptors: Future targets for breast cancer therapy?.. 12:C184-C184. 2013
Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors. 12:542-552. 2013
ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer. 10:1876-1885. 2011
Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts. 10:57-68. 2011
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. 8:64-74. 2009
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. 6:570-577. 2007
Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. 5:3303-3311. 2006
Role of the transcription factor Ets-1 in cisplatin resistance. 3:823-832. 2004
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.. 1:545-552. 2002

has subject area

1112 Oncology and Carcinogenesis (FoR)
1115 Pharmacology and Pharmaceutical Sciences (FoR)
Oncology & Carcinogenesis (Science Metrix)